12,363 Shares in TG Therapeutics, Inc. $TGTX Bought by Quantbot Technologies LP

Quantbot Technologies LP purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 12,363 shares of the biopharmaceutical company’s stock, valued at approximately $679,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. BlackRock Inc. purchased a new stake in TG Therapeutics during the second quarter worth $1,211,429,000. Vanguard Group Inc. boosted its stake in shares of TG Therapeutics by 2.1% during the fourth quarter. Vanguard Group Inc. now owns 15,841,002 shares of the biopharmaceutical company’s stock valued at $472,220,000 after acquiring an additional 319,703 shares during the last quarter. State Street Corp lifted its holdings in TG Therapeutics by 4.7% in the 4th quarter. State Street Corp now owns 8,479,999 shares of the biopharmaceutical company’s stock valued at $252,789,000 after purchasing an additional 379,380 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of TG Therapeutics by 35.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,051,132 shares of the biopharmaceutical company’s stock worth $61,144,000 after purchasing an additional 531,759 shares during the last quarter. Finally, Pictet Asset Management Holding SA grew its holdings in shares of TG Therapeutics by 19.6% during the first quarter. Pictet Asset Management Holding SA now owns 1,747,373 shares of the biopharmaceutical company’s stock worth $58,048,000 after buying an additional 286,325 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research report on Wednesday, July 29th. Bank of America lifted their target price on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a research note on Tuesday, July 7th. HC Wainwright reiterated a “buy” rating and issued a $78.00 price target on shares of TG Therapeutics in a report on Tuesday, August 4th. Zacks Research raised TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, June 1st. Finally, B. Riley Financial raised their price objective on TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a report on Monday, July 27th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $63.00.

TG Therapeutics Trading Up 1.3%

NASDAQ TGTX opened at $55.72 on Friday. The company has a market cap of $8.53 billion, a P/E ratio of 20.34, a P/E/G ratio of 2.36 and a beta of 1.62. TG Therapeutics, Inc. has a 12 month low of $26.76 and a 12 month high of $59.30. The company has a debt-to-equity ratio of 1.23, a current ratio of 4.27 and a quick ratio of 3.72. The company has a 50-day moving average of $53.36 and a 200-day moving average of $41.74.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.26). TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.The company had revenue of $240.34 million during the quarter, compared to analyst estimates of $229.77 million. During the same period in the prior year, the business posted $0.17 earnings per share. TG Therapeutics’s revenue was up 70.2% on a year-over-year basis. As a group, equities analysts predict that TG Therapeutics, Inc. will post 0.92 earnings per share for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.